Dillan DiNardo

Developing the next generation of psychedelic therapeutics for mental health indications at Mindstate Design Labs. We design novel altered states of consciousness using machine learning, human experiential data, and molecular pharmacology. Our lead program is in IND-enabling studies.Mindstate Design Labs was in the Y Combinator S21 batch and raised a seed round led by Initialized Capital with participation from a number of other VCs and angels including founders of OpenAI, Neuralink, AngelList, Coinbase, Instacart, and Twitch.You can learn more about psychedelic therapy here:Nature: How Ecstasy and Psilocybin are Shaking Up Psychiatryhttps://www.nature.com/articles/d41586-021-00187-9New York Times: The Psychedelic Revolution is Coming. Psychiatry May Never Be the Same.https://www.nytimes.com/2021/05/09/health/psychedelics-mdma-psilocybin-molly-mental-health.htmlWall Street Journal: How Psychedelic Drugs Are Making a Comeback to Treat Depression.https://www.wsj.com/podcasts/wsj-the-future-of-everything/how-psychedelic-drugs-are-making-a-comeback-to-treat-depression/e4d6a4ce-9b21-40c6-8741-91f97a53cd81Previously I worked in venture investing and spinouts at UPMC Enterprises, the internal venture arm of UPMC. Prior to UPMC Enterprises I was a transaction-focused consultant, covering the full investment life cycle from angel and seed-stage startup funding rounds to Fortune 500 mergers, acquisitions, and divestitures.